Athira Pharma, Inc. — Director's Dealing 2022

Jan 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-01-04

Reporting Person: MILESON GLENNA (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-18	Common Stock	A	931	$12.51	Acquired	90755	Direct
2022-01-04	Common Stock	M	6305	$1.35	Acquired	97060	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-04	Stock Option (Right to Buy)	$1.35	M	6305	Disposed	2028-12-17	Common Stock (6305)	Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).

F2: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.

F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.

F4: The shares subject to the option fully vested on January 1, 2022.